Clinical Research Directory

Inclusion Criteria: * -Patients of any age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology. * Patients must sign an informed consent form (ICF) voluntarily and be able to understand and comply with the requirements of the study; * Patients must be 18 to 75 years of age (including cut-offs) on the date of signing the informed consent form, regardless of gender; * Patients must received treatment with a chemotherapy regimen . * Patients must have ≥ grade 1 sensory chemotherapy-induced peripheral neuropathy (CIPN) with NRS ≥ 4/10 according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE) v.5.0 grading scale * Eastern Cooperative Oncology Group performance status (ECOG PS): 0-2; * Expected survival of ≥ 3 months * There is no maximum number of prior medical therapies. Exclusion Criteria: * History of allergic reactions attributed to compounds of similar chemical or biologic composition to duloxetine, amitriptyline and gabapentin * Pregnant women are excluded from this study. * Life expectancy less than 6 months * Inability or unwillingness to comply with research protocols. * Patients with the presence of active brain or meningeal metastases. * Patients with the presence of uncontrolled closed-angle glaucoma. * Patients with the presence of neuropathy caused by any type of nerve compression as diabetes. * The presence of mental illness, epilepsy, mania, suicidal depression, dementia or alcohol or drug abuse that may have an impact on compliance with trial requirements. * The presence of comorbid cardiovascular disease, including but not limited to: (1) New York Heart Association (NYHA) criteria ≥ grade 2 heart failure; (2) severe/unstable angina pectoris; (3) myocardial infarction or cerebrovascular accident within 6 months prior to first dose; (4) atrial fibrillation and supraventricular or ventricular arrhythmias requiring treatment; (5) pre-existing symptomatic superior vena cava syndrome; (6) corrected QT interval (QTc) \> 450 ms (men); QTc \> 470 ms (women); (7) hypertensive disease not controlled by antihypertensive medication: systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg; * Patients with other medical history or evidence of disease that has the potential to confound trial results are excluded from the study,